Hematologic Malignancies

KRD Maintenance: Another Alternative for Newly Diagnosed Multiple Myeloma?

By Dr. Harsh Parmar Hackensack Meridian Health   In an unplanned interim analysis of an international phase-III trial (ATLAS) by…

2 years ago

FDA Approves Pemigatinib in Patients with Relapsed/Refractory Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement: Finally a Treatment Option for a Challenging Disease

By Dr. Abhishek A. Mangaonkar Mayo Clinic   The phase 2 FIGHT-203 trial (NCT#03011372) studied 28 patients with relapsed/refractory myeloid/lymphoid…

2 years ago

Chemotherapy Free Ph+ ALL Induction? The Promise of Ponatinib plus Blinatumomab

Dr. Luke Fletcher Willamette Valley Cancer Institute & Research Center   Philadelphia positive acute lymphoblastic leukemia treatment has been driven…

2 years ago

AGILE trial—Ivosidenib plus Azacitidine versus Azacitidine in IDH1 Mutated Acute Myeloid Leukemia

Dr. Aditi Sharma of Barbara Ann Karmanos Cancer Institute & Dr. Abhishek Mangaonkar of Mayo Clinic   In the phase…

2 years ago

Imetelstat in Low-Risk MDS for Transfusion Independence: the Phase 3 IMerge Study

By Luke Fletcher, MD Willamette Valley Cancer Institute & Research Center   Imetelstat, a telomerase inhibitor, has shown interesting promise…

2 years ago

Four Oncology Conferences Held in October 2021

The Binaytara Foundation organized three in-person oncology conferences in October 2021. The 2021 Updates in Hematologic Malignancies and the 2021…

3 years ago